FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
What happened
In December 2025, FDA reviewed https://zappyhealth.com and found it offered compounded semaglutide, tirzepatide, and liraglutide drug products. FDA said pictured labels identify Zappy as the compounder although it is not, and the site made claims that compared the products to Wegovy, Saxenda, and Zepbound and called them proven and clinically studied, implying FDA approval or evaluation. FDA cited the products as misbranded.
What FDA found
The website showed labels with "Zappy" on compounded drugs, suggesting Zappy made them when it did not, so FDA called the labeling false or misleading (misbranded).
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)The website compared compounded semaglutide, tirzepatide, and liraglutide to the active ingredients in Wegovy, Saxenda, and Zepbound, implying the compounded drugs were FDA-approved or evaluated.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website called the drugs "a proven medication" and said they were "clinically studied and shown to deliver powerful results," implying safety and effectiveness that FDA says were not established for these compounded products.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving, delivering, or offering delivery of the misbranded drugs is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, send OCQC/CDER a written response describing steps taken to address violations, identify entities that produce the compounded products, provide sample labeling, and address or remove misleading website claims. If you cannot complete the matter in that time, state why and when you will.
Who should pay attention
- telehealth platforms selling compounded GLP-1 drugs
- marketing and website teams for drug sellers
- compounders whose products are advertised by third-party platforms
This is a summary. Read the original letter on fda.gov.